EcoVadis is a globally trusted provider of business sustainability ratings with a network of more than 130,000 rated companies. Its comprehensive evaluations encompass critical domains including Environment, Labor and Human Rights, Ethics, and Sustainable Procurement, offering organizations detailed analyses and strategies for sustainability improvement. These evaluations are pivotal in bolstering a company's international reputation and competitive positioning.
“Sustainable development is at the heart of our corporate strategy,” said Dr. Minmin Yang, Founder of PharmaBlock. “Our exceptional performance in EcoVadis’ recent evaluation addresses our unwavering commitment to ESG excellence. This accolade not only signifies the company’s substantial strides in ESG performance but also affirms our position at the forefront of global pharmaceutical R&D and manufacturing.”
PharmaBlock is honored to have its efforts in ESG and sustainability recognized. In August 2024, the company's Wind ESG rating was elevated to "AA". Furthermore, in September, PharmaBlock was named as a finalist for the CPHI Pharma Awards 2024 in the Sustainability category. This nomination follows the company’s receipt of the CPHI China ESG Sustainability Influencer Award in June, marking another opportunity to secure a prestigious industry sustainability honor.
In recent years, PharmaBlock has actively participated in the United Nations Global Compact (UNGC) and submitted its application to the Science Based Targets initiative (SBTi), affirming its steadfast commitment to global sustainable development goals. The company has proactively aligned its management systems with international ESG standards, expanding its certification portfolio beyond ISO 9001 Quality Management, ISO 14001 Environmental Management and ISO 45001 Occupational Health and Safety Management to include ISO 50001 Energy Management, ISO/IEC 27001 Information Security Management, and GB/T 39604-2020 Social Accountability (SA) Management. These accreditations signify PharmaBlock’s substantial progress in energy efficiency, lean operations, and social responsibility governance, emphasizing the company’s pursuit of excellence in sustainability and operational performance.
PharmaBlock is dedicated to its mission of "We innovate Chemistry for a Greener and Healthier World," striving to drive sustainable development within the industry through innovative advancements in chemistry and low-carbon technologies. Leveraging state-of-the-art techniques such as continuous flow processes and micro-packed hydrogenation, the company has received the ACS CMO Excellence in Green Chemistry Award for two consecutive years in 2023 and 2024. This recognition underscores PharmaBlock's commitment to providing clients with more efficient, environmentally friendly, and safer drug development and manufacturing services, but also sets a benchmark for driving the industry's green transformation.
In future, PharmaBlock will intensify its ESG efforts by prioritizing customer needs and driving growth through pioneering innovations in chemistry and low-carbon technologies. In unity with industry partners, the company is steadfast in its commitment to enhancing the efficiency of pharmaceutical research and development, collectively steering the industry toward a greener and more sustainable future.
EcoVadis is a global leader in corporate sustainability ratings, specializing in evaluating companies' performance in supply chain sustainability. Its assessments cover four key areas: Environment, Labor & Human Rights, Business Ethics, and Sustainable Procurement. EcoVadis has become an essential benchmark for businesses worldwide to measure and improve their sustainability practices and performance.
﹀
﹀
﹀
【要闻】AA级！药石科技Wind ESG评级跃升
引领绿色化学与低碳制造丨药石科技CPHI 2024之行
【要闻】药石科技蝉联2024 ACS CMO绿色化学卓越奖
PharmaBlock (Stock code: 300725.SZSE) is a leading provider of innovative chemistry products and services throughout the pharmaceutical R&D process and commercial manufacturing. Its dedication to advancing innovation in chemistry and low-carbon manufacturing supports partners to accelerate drug R&D, ensure consistent quality, reduce R&D and manufacturing cost, and foster a greener and more sustainable future. Officially operated in 2008, PharmaBlock has partnered with almost all the top 20 pharmaceutical companies and hundreds of biotech companies around the world. Its core businesses began with building blocks for drug discovery, and after establishing experience developing robust and scalable processes for manufacturing thousands of compounds, PharmaBlock grew into a research, development & GMP manufacturing service partner for global pharmaceutical and biotech companies. The company has also developed a comprehensive suite of solutions, featuring flow chemistry, micropacked bed hydrogenation, biocatalysis, heterogeneous catalysis, etc., to reduce the carbon footprint, address the chemical challenges, and make pharmaceutical production more efficient and safer.
Website: www.pharmablock.com
Product Website: product.pharmablock.com
Contact to us
PharmaBlock Sciences (Nanjing), Inc.
Add: 81 Huasheng Road, Jiangbei New District
Tel: +86-400 025 5188
Fax: +86-25 8691 8232
E-mail: sales@pharmablock.com
PharmaBlock (USA), Inc.
Add: 777 Schwab Road, Unit D, Hatfield, PA 19440, USA
Tel: +1-877 878 5226 / 267 649 7271
Fax: +1-267 222 7551
E-mail: salesusa@pharmablock.com
